Aducanumab

View All

alzheimers-disease-pipeline-therapies-drugs-therapeutics
Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is a lead cause of dementia in approximately 5.8 million Americans. Further, it is estimated that the number will soar to 13.5 million by 2050.  Owing to the R&D done in understanding Alzheimer’s disease so far, it has been clear t...

Find More

pharma-biotech-news-updates-for-biogen-pfizer-viiv-calliditas
Pfizer’s COVID-19 Vaccine; Calliditas’ NefIgArd trial; ViiV’s HIV Prevention Treatment; Biogen’s Aducanumab Rejection

Pfizer's COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, the pharma titan, Pfizer, announced that its COVID-19 vaccine is more than 90% effective in preventing coronavirus infection. Tedros Adhanom Ghebrey...

Find More

Alzheimer's disease
Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab

Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer's disease called futility analysis. The drug was designed to help patients struggling with mild cognitive impairmen...

Find More

Alzheimer’s drug fails! Is it time to move on?

Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...

Find More